Article and Video CATEGORIES

Cancer Journey

Search By

Dr. Jack West is a medical oncologist and thoracic oncology specialist who is the Founder and previously served as President & CEO, currently a member of the Board of Directors of the Global Resource for Advancing Cancer Education (GRACE)

 

Interview with Dr. Suresh Ramalingam on First Line and Maintenance Therapy for Advanced NSCLC
Author
Howard (Jack) West, MD

The ASCO meeting I'm at right now is so busy that there really isn't time to write a new post (though I'm still "tweeting from the meeting"). Though the talk show hows just air re-runs of old shows when they're on vacation, I'm trying to continue to add new content to the website during this time (and it's about as far from a vacation as anyone has in Orlando).

Here's an interview I did with Dr. Suresh Ramalingam, medical oncologist and Director of the Thoracic Oncology Program at Winship Cancer Institute at Emory University. It covers the current status of initial treatment for advanced NSCLC, including controversies and shifting standards for first line and then the transition into maintenance therapy. There's also an associated slide set (as a pdf file), a transcript, and a link to the audio (mp3) version.

[powerpress]

ramalingam-podcast-figures-on-first-line-rx-and-maint2

ramalingam-first-line-and-maintenance-rx-transcript

Ramalingam First Line and Maintenance Rx for Adv NSCLC Audio Podcast

Next Previous link

Previous PostNext Post

Related Content

Image
Videoteca de Cáncer de Pulmon - 2025
Video
Como parte de la Videoteca de Cáncer de Pulmón en Español 2025, oncólogos expertos discuten las opciones de tratamiento y la información más emergente en cáncer de pulmón. El Dr. Raez aborda la terapia para cánceres de pulmón EGFR y ALK, además de analizar otros tres temas de actualidad. La Dra. Viola y la Dra. Riaño también contribuyen a esta videoteca, cada una presentando tres temas relevantes sobre el cáncer de pulmón.
Article
The journey to conquer lung cancer is paved with scientific discovery, and the identification of the EGFR and ALK genes as crucial players marks a significant milestone. Unraveling how mutations in these seemingly small segments of our DNA can unleash the destructive force of cancer has opened up exciting new therapeutic avenues. This exploration delves into the cutting-edge world of EGFR and ALK-targeted therapies, highlighting the progress made and the ongoing quest for even more effective and personalized strategies to combat this formidable disease.
Image
Rare cancers
Video
In these videos,  Dr. Jared Weiss gives a brief overview of NUT Carcinoma, discusses treatment options and possible future treatment.  To watch the complete playlist, click here.